COMMUNIQUÉS West-GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences
31/01/2024
VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]
Half-year report
31/01/2024
DXS INTERNATIONAL PLC (AQSE: DXSP) HALF YEAR RESULTS DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to provide shareholders with its unaudited interim results [...]
BioSenic provides support to forthcoming European conference on graft-versus-host disease
31/01/2024
Mont-Saint-Guibert, Belgium, January 31, 2024, 7.00 am CEST – BioSenic (Euronext Brussels and Paris: BIOS) , the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, [...]
BioSenic soutient la prochaine conférence européenne sur la maladie du greffon contre l'hôte
31/01/2024
Mont-Saint-Guibert, Belgique, le 31 janvier 2024, à 7h00 CEST – BIOSENIC ( Euronext Bruxelles et Paris : BIOS) , société spécialisée en essais cliniques dans les maladies auto-immunes et inflammatoires graves et la [...]
Release date of annual report 2023 for ALK and webcast
31/01/2024
On Thursday, 8 February 2024 in the afternoon, ALK ( ALKB:DC / OMX: ALK B / AKBLF ) releases its annual report for 2023. ALK will host an online meeting for analysts and institutional investors that day at 4.00pm (CET) [...]
Nexstim Plc: Proposals of the Shareholder’s Nomination Board to the Annual General Meeting
31/01/2024
Company announcement, Helsinki, 31 January 2024 at 10 AM (EET) Nexstim Plc: Proposals of the Shareholder’s Nomination Board to the Annual General Meeting The Shareholder’s Nomination Board of Nexstim Corporation (NXTMH: [...]
LifeArc makes multi-million pound investment to support drug discovery in sub-Saharan Africa
31/01/2024
LifeArc makes multi-million pound investment to support drug discovery in sub-Saharan Africa LifeArc and the Bill & Melinda Gates Foundation are jointly investing £6 million ($7.2m) to enhance drug discovery [...]
Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023
31/01/2024
Bagsværd, Denmark, 31 January 2024 - Financial report for the period 1 January 2023 to 31 December 2023 Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion [...]
Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA®
31/01/2024
Press Release Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA ® January 31, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA [...]
Nicox : Prolongation de 5 ans de la durée d’un brevet américain couvrant le latanoprostene bunod commercialisé sous le nom de VYZULTA®
31/01/2024
Communiqué de presse Nicox : Prolongation de 5 ans de la durée d’un brevet américain couvrant le latanoprostène bunod commercialisé sous le nom de VYZULTA ® 31 janvier 2024 – diffusion à 7h30 Sophia Antipolis, France [...]
ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry
31/01/2024
ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry ANT-01 is in late-stage development as an adjunctive treatment for major depressive disorder ( [...]
Geneva Court Grants Temporary Moratorium to ObsEva
31/01/2024
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today [...]
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
31/01/2024
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 31, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and [...]
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
31/01/2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko ® approved for all indications of reference medicine Tyruko ® biosimilar to treat adults with highly active relapsing [...]
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
31/01/2024
Ad hoc announcement pursuant to Art. 53 LR Full year (continuing operations 2 ) Net sales grew +10% (cc, +8% USD) with core operating income growing +18% (cc, +11% USD) Sales growth was mainly driven by continued strong [...]
Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III
31/01/2024
Annonce événementielle au sens de l’art. 53 RC Exercice complet (activités poursuivies 2 ) Hausse de +10 % (tcc, +8 % USD) du chiffre d’affaires net et de +18 % (tcc, +11 % USD) du résultat opérationnel core La [...]
Vaxcyte Announces Pricing of $750 Million Public Offering
31/01/2024
SAN CARLOS, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]
Immunocore Prices Upsized Convertible Senior Notes Offering
31/01/2024
Immunocore Prices Upsized Convertible Senior Notes Offering (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, January 30, 2024) Immunocore Holdings plc (Nasdaq: IMCR) today announced the pricing of $ [...]
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
31/01/2024
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company that [...]

Pages